Home > News > DRC Acquires Royalties from Nanogen
October 4th, 2006
DRC Acquires Royalties from Nanogen
Abstract:
Drug Royalty Corporation Inc. (DRC) and Nanogen Inc. (Nasdaq: NGEN) announced today that they have
entered into an agreement for a trust managed by DRC to acquire an interest in royalties on the MGB(TM) (minor groove binder) technology owned by Nanogen for 5' nuclease real-time PCR applications in the biomedical research market.
Source:
prnewswire
Related News Press |
Nanomedicine
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Advances in priming B cell immunity against HIV pave the way to future HIV vaccines, shows quartet of new studies May 17th, 2024
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Announcements
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Finding quantum order in chaos May 17th, 2024
Oscillating paramagnetic Meissner effect and Berezinskii-Kosterlitz-Thouless transition in cuprate superconductor May 17th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||